 | Up a level |
Llovet, J; Merle, P; Weiss, KH; Yau, T; Ross, P; Mazzaferro, V; Blanc, JF; Ma, Y; Yen, C; Kocsis, J; Choo, S; Sukeepaisarnjaroen, W; Gerolami, R; Dufour, Jean-François; Gane, E; Ryoo, BY; Peck, M; Dao, T; Yeo, W; Lamlertthon, W; ... (November 2016). Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC). Hepatology, 64(1Suppl), 621A-621A. Wiley Interscience
Cummings, J; Zweifel, M; Smith, N; Ross, P; Peters, J; Rustin, G; Price, P; Middleton, M R; Ward, T; Dive, C (2012). Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. British journal of cancer, 106(11), pp. 1766-71. Basingstoke: Nature Publishing Group 10.1038/bjc.2012.165
